Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Ojo-Amaize, Edward Conley, J. Peter (1994)
Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 18 Suppl 1
(1994)
Development of the WHOQOL: Rationale and current status
M. Sharpe, K. Hawton, S. Simkin, C. Surawy, A. Hackmann, I. Klimes, T. Peto, D. Warrell, V. Seagroatt (1996)
Cognitive behaviour therapy for the chronic fatigue syndrome: a randomised controlled trialBMJ, 312
C. Paterson (1996)
Measuring outcomes in primary care: a patient generated measure, MYMOP, compared with the SF-36 health surveyBMJ, 312
F. Diaz-Mitoma, E. Turgonyi, Ashok Kumar, W. Lim, L. Larocque, B. Hyde (2003)
Clinical Improvement in Chronic Fatigue Syndrome Is Associated with Enhanced Natural Killer Cell-Mediated Cytotoxicity: The Results of a Pilot Study with Isoprinosine®Journal of Chronic Fatigue Syndrome, 11
L. Morrison, W. Behan, P. Behan (1991)
Changes in natural killer cell phenotype in patients with post‐viral fatigue syndromeClinical & Experimental Immunology, 83
(1996)
NK immunomodulatory function in 27 cancer patients by MGN-3, a modified arabinoxylan from rice bran
T. Chalder, G. Berelowitz, T. Pawlikowska, L. Watts, S. Wessely, D. Wright, E. Wallace (1993)
Development of a fatigue scale.Journal of psychosomatic research, 37 2
M. Caligiuri, C. Murray, D. Buchwald, H. Levine, P. Cheney, Daniel Peterson, A. Komaroff, J. Ritz (1987)
Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome.Journal of immunology, 139 10
Nancy KLIMASl, Fernando Salvato, R. Morgan, M. Fletcher (1990)
Immunologic abnormalities in chronic fatigue syndromeJournal of Clinical Microbiology, 28
F. Brouwers, S. Werf, G. Bleijenberg, L. Zee, J. Meer (2002)
The effect of a polynutrient supplement on fatigue and physical activity of patients with chronic fatigue syndrome: a double-blind randomized controlled trial.QJM : monthly journal of the Association of Physicians, 95 10
Laura Solomon, W. Reeves (2004)
Factors influencing the diagnosis of chronic fatigue syndrome.Archives of internal medicine, 164 20
J. Prins, G. Bleijenberg, E. Bazelmans, L. Elving, T. Boo, J. Severens, G. Wilt, P. Spinhoven, J. Meer (2001)
Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trialThe Lancet, 357
S. Reid, T. Chalder, A. Cleare, M. Hotopf, S. Wessely (2002)
Chronic fatigue syndrome.[update in Clin Evid. 2002 Dec;(8):1075-88; PMID: 12603930]Clinical evidence
A descriptive Questionnaire-Based Study on the use of BioBran (MGN-3) in Chronic Fatigue Syndrome. Townsend Letter for Doctors and Patients
M. Ghoneum (1998)
Enhancement of human natural killer cell activity by modified arabinoxylane from rice bran (MGN-3)International Journal of Immunotherapy, 14
K. Fukuda, S. Straus, I. Hickie, M. Sharpe, J. Dobbins, A. Komaroff (1994)
The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and StudyAnnals of Internal Medicine, 121
Huston Gj (1987)
The Hospital Anxiety and Depression Scale.The Journal of rheumatology, 14 3
Umberto Tirelli, Giuseppe Marotta, Salvatore Improta, A. Pinto (1994)
Immunological Abnormalities in Patients with Chronic Fatigue SyndromeScandinavian Journal of Immunology, 40
(2004)
BMC Health Services Research BioMed Central
E. Barker, S. Fujimura, M. Fadem, A. Landay, Jay Levy (1994)
Immunologic abnormalities associated with chronic fatigue syndrome.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 18 Suppl 1
M. Lyall, M. Peakman, S. Wessely (2003)
A systematic review and critical evaluation of the immunology of chronic fatigue syndrome.Journal of psychosomatic research, 55 2
Background: Previous research has suggested that natural killer (NK) cell activity may be reduced in patients with chronic fatigue syndrome (CFS).Aim: To evaluate the effectiveness of a putative NK cell stimulant, BioBran MGN-3, in reducing fatigue in CFS patients.Design: Randomized, double-blind, placebo-controlled trial.Methods: We recruited 71 patients with CFS (according to the Centers for Disease Control 1994 criteria) attending an out-patient specialist CFS service. Participants were given oral BioBran MGN-3 for 8 weeks (2 g three times per day) or placebo equivalent. The primary outcome measure was the Chalder physical fatigue score. Self-reported fatigue measures, self-assessment of improvement, change in key symptoms, quality of life, anxiety and depression measures were also included.Results: Data were complete in 64/71 patients. Both groups showed marked improvement over the study duration, but without significant differences. Mean improvement in the Chalder fatigue score (physical scale) was 0.3 (95%CI –2.6 to 3.2) lower in the BioBran group.Discussion: The findings do not support a specific therapeutic effect for BioBran in CFS. The improvement showed by both groups over time highlights the importance of placebo controls when evaluating interventions in CFS.
QJM: An International Journal of Medicine – Oxford University Press
Published: Jul 1, 2006
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.